Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

被引：12

作者：

Smith, Brandon I. ^{[1
]}

Engel, Priya ^{[2
]}

Wu, Jashin ^{[3
]}

机构：

[1] Drexel Univ, Coll Med, Philadelphia, PA USA

[2] Calif Univ Sci & Med, Colton, CA USA

[3] Univ Miami, Miller Sch Med, Miami, FL 33136 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2023年 / 388卷 / 24期

关键词：

D O I：

10.1056/NEJMc2304782

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

To the Editor: Silverberg and colleagues (March 23 issue)(1) conclude, on the basis of two phase 3 trials, that lebrikizumab therapy was safe and effective for the management of moderate-to-severe atopic dermatitis in adolescents and adults. Although their trials showed promising results, we believe that there are a few points to consider. The lack of racial diversity in the trial may hinder the generalizability of the results. A majority of the patients in the trials were White (approximately 68% in trial 1 and 59% in trial 2). Black and Asian patients comprised approximately 10% and 23% of the patients, respectively, . . .

引用

页码：2299 / 2300

页数：2

共 9 条

[1] Racial differences in atopic dermatitis [J].

Brunner, Patrick M. ;

Guttman-Yassky, Emma .

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 122 (05) :449-455

[2] Pruritus as a Distinctive Feature of Type 2 Inflammation [J].

Garcovich, Simone ;

Maurelli, Martina ;

Gisondi, Paolo ;

Peris, Ketty ;

Yosipovitch, Gil ;

Girolomoni, Giampiero .

VACCINES, 2021, 9 (03)

[3] Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis A Phase 2b Randomized Clinical Trial [J].

Guttman-Yassky, Emma ;

Blauvelt, Andrew ;

Eichenfield, Lawrence F. ;

Paller, Amy S. ;

Armstrong, April W. ;

Drew, Janice ;

Gopalan, Ramanan ;

Simpson, Eric L. .

JAMA DERMATOLOGY, 2020, 156 (04) :411-420

[4] Atopic dermatitis in diverse racial and ethnic groupsVariations in epidemiology, genetics, clinical presentation and treatment [J].

Kaufman, Bridget P. ;

Guttman-Yassky, Emma ;

Alexis, Andrew F. .

EXPERIMENTAL DERMATOLOGY, 2018, 27 (04) :340-357

[5] Mechanistic insights into the antipruritic effects of lebrikizumab, an anti-IL-13 mAb [J].

Miron, Yannick ;

Miller, Paul E. ;

Hughes, Chloe ;

Indersmitten, Tim ;

Lerner, Ethan A. ;

Cevikbas, Ferda .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 150 (03) :690-700

[6] Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis [J].

Silverberg, Jonathan I. ;

Guttman-Yassky, Emma ;

Thaci, Diamant ;

Irvine, Alan D. ;

Gold, Linda Stein ;

Blauvelt, Andrew ;

Simpson, Eric L. ;

Chu, Chia-Yu ;

Liu, Zhuqing ;

Lima, Renata Gontijo ;

Pillai, Sreekumar G. ;

Seneschal, Julien .

NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (12) :1080-1091

[7] Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis [J].

Simpson, E. L. ;

Bieber, T. ;

Guttman-Yassky, E. ;

Beck, L. A. ;

Blauvelt, A. ;

Cork, M. J. ;

Silverberg, J. I. ;

Deleuran, M. ;

Kataoka, Y. ;

Lacour, J. -P. ;

Kingo, K. ;

Worm, M. ;

Poulin, Y. ;

Wollenberg, A. ;

Soo, Y. ;

Graham, N. M. H. ;

Pirozzi, G. ;

Akinlade, B. ;

Staudinger, H. ;

Mastey, V. ;

Eckert, L. ;

Gadkari, A. ;

Stahl, N. ;

Yancopoulos, G. D. ;

Ardeleanu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (24) :2335-2348

[8] Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation [J].

Stott, Bryony ;

Lavender, Paul ;

Lehmann, Sarah ;

Pennino, Davide ;

Durham, Stephen ;

Schmidt-Weber, Carsten B. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 132 (02) :446-+

[9] Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2) [J].

Wollenberg, A. ;

Blauvelt, A. ;

Guttman-Yassky, E. ;

Worm, M. ;

Lynde, C. ;

Lacour, J. -P. ;

Spelman, L. ;

Katoh, N. ;

Saeki, H. ;

Poulin, Y. ;

Lesiak, A. ;

Kircik, L. ;

Cho, S. H. ;

Herranz, P. ;

Cork, M. J. ;

Peris, K. ;

Steffensen, L. A. ;

Bang, B. ;

Kuznetsova, A. ;

Jensen, T. N. ;

osterdal, M. L. ;

Simpson, E. L. .

BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) :437-449

← 1 →